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Randomised, double blind placebo controlled trial of
pentoxifylline in the treatment of venous leg ulcers
J J Dale, C V Ruckley, D R Harper, B Gibson, E A Nelson, R J Prescott
Abstract
Objective To determine whether pentoxifylline 400
mg (Trental 400) taken orally three times daily, in
addition to ambulatory compression bandages and
dressings, improves the healing rate of pure venous
ulcers.
Design Randomised, double blind placebo controlled
trial, parallel group study of factorial design,
permitting the simultaneous evaluation of alternative
pharmaceutical, bandaging, and dressings materials.
Setting Leg ulcer clinics of a teaching and a district
general hospital in southern Scotland.
Participants 200 patients with confirmed venous
ulcers and in whom other major causal factors were
excluded.
Interventions Pentoxifylline 400 mg three times daily
or placebo.
Main outcome measure Complete healing (full
epithelialisation) of all ulcers on the trial leg.
Results Complete healing occurred in 65 of the 101
(64%) patients receiving pentoxifylline and 52 of the
99 (53%) patients receiving placebo.
Conclusions The difference in the healing rates
between patients taking pentoxifylline and those
taking placebo did not reach statistical significance.
Introduction
Leg ulcers have a prevalence of about 1% of the adult
population in Great Britain.1 2 The most recent (1992)
estimate of the cost of treatment to the NHS was
around £400 million per annum.3 Several clinical trials
have shown that treatment with carefully chosen and
meticulously applied ambulatory compression band›
ages and dressings for several months resulted in
failure in 30% to 60% of patients with ulcers.4–6 A drug
that improved healing rates would be a useful adjunct
to other treatment methods. Pentoxifylline, a vasoactive
drug that reduces leucocyte adhesion and has mild
fibrinolytic effects, is potentially such an agent, since it
might interfere with two processes believed to occur in
the pathogenesis of venous leg ulceration.7 8
Pentoxifylline is currently prescribed for the
treatment of peripheral arterial disease and its compli›
cations. The normal dose is 400 mg two or three times
daily at a cost of £24.93 for a pack of 90×400 mg tab›
lets at September 1998 prices.9 If the drug is taken
three times daily, as in our trial, the daily cost is 83p.
Previous clinical trials investigating the possible use
of pentoxifylline in the treatment of leg ulcers have
produced conflicting results.10–12 It is possible that the
outcome of some of these studies was influenced by the
inclusion of patients with conditions that might be
affected differently by pentoxifylline, such as those with
an element of arterial impairment. The Lothian and
Forth Valley Leg Ulcer Study Group therefore decided
to conduct a trial in patients with strictly defined
venous ulcers, to determine whether pentoxifylline
would be a useful adjunct to dressings and ambulatory
compression therapy in this group.
Our primary aim was to determine whether
pentoxifylline 400 mg (Trental 400; Hoechst Marion
Roussel, Uxbridge) taken orally three times daily, in
addition to ambulatory compression bandages and
dressings, improves the healing rate of pure venous
ulcers. Our secondary aim was to test the safety and
tolerability of the drug when used for this purpose.
Participants and methods
Trial structure
Our trial formed the major component of a linked
series of trials, with all patients with leg ulcers
considered for entry into one of the trials depending
on the cause of ulceration. This paper reports the trial
on ulcers of proved venous disease, uncomplicated by
diabetes, arterial impairment, or other systemic condi›
tions. The trial used a two centre randomised, parallel
group, factorial design. The treatments we evaluated
were alternative pharmaceutical, bandaging, and
dressings materials. The pharmaceutical treatment was
investigated double blind, but this was not feasible for
the other treatments. The statistical design of the whole
trial has been described in detail elsewhere.13 Our
paper concentrates solely on the pharmaceutical com›
ponent of the study. The results of the dressings and
bandages arms and the arterial stratum will be
reported separately elsewhere.
Exclusion criteria
The study was approved by the ethical committee at
each centre. Informed consent was obtained from
each patient before entry to the trial. Eligible patients
were aged 18 years or over, with pure venous ulcers
present for at least 2 months. For the purposes of the
trial “pure” venous ulcers were defined as those where
there was established venous disease, confirmed by
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ultrasonography, and in which other major causal fac›
tors were excluded. Criteria for exclusion of potential
participants were: (a) myocardial infarction in the past
3 months, major haemorrhage in the past 8 weeks,
poor compliance with treatment, or hypersensitivity to
methylxanthines, pentoxifylline, and drinks contain›
ing cola or caffeine; (b) systematic treatment with
corticosteroids, cytotoxic agents, naftidrofuryl, pen›
toxifylline, oxerutin, anticoagulant or fibrinolytic
agents, or an experimental drug that was currently
being taken or taken within the past 3 months; (c)
lumbar sympathectomy within the past 3 weeks; (d) the
presence of right heart failure, a serum creatinine
concentration greater than 180 ìmol/l, hepatic insuf›
ficiency, diabetes mellitus, malignant disease, rheuma›
toid arthritis, or other severe connective disorder,
limited physical capacity or total immobility, or an
infected ulcer or gangrene at the ulcer site; (e) an ulcer
size of less than 1 cm in one dimension; (f) the
presence of ulcer for less than 2 months; (g) admission
to hospital likely to be required for more than 10 days;
(h) pregnancy, lactation, or women not using adequate
contraception; and (i) a life expectancy of less than 6
months.
Reference ulcer
All patients presenting at the leg ulcer clinics of the
Edinburgh and Falkirk royal infirmaries were consid›
ered. Each patient was included only once. Where the
ulcers were bilateral, the leg with the largest ulcer was
designated as the trial leg, and the largest ulcer on the
trial leg was designated as the reference ulcer. All refer›
ence ulcers were at least 1 cm in the major diameter.
Patients were randomised in a 1:1 ratio, by centre,
to receive pentoxifylline 400 mg three times daily or
matching placebo, and they were also randomised to
receive one of the two bandaging treatments and one
of the two dressings (see website). The treatments were
packaged, supplied, and labelled with consecutive
patient numbers in each centre by the manufacturer.
The pentoxifylline and placebo tablets looked identical
to ensure that the study was double blind with respect
to drug. On acceptance into the trial, participants were
assigned the next available patient number. The dress›
ings and bandages were allocated by opening the cor›
respondingly numbered, sealed, opaque envelope.
Participants
We excluded 239 of 525 (45.5%) potential
participants—76 for ulcer related reasons: ulcers too
small (50 patients), diabetic patient needing compres›
sion therapy,11 healed ulcer or not an ulcer,6 short
duration,4 and other5; 56 owing to the patient’s
condition or diseases: immobile or frail,14 required
hospital admission,11 raised serum creatinine concen›
tration,8 mental illness,5 malignancy,4 communication
difficulties,3 heart failure,2 hepatic insufficiency,2 death
before randomisation,1 and other6; 49 who refused to
participate; 25 for administrative reasons: geographi›
cal,12 non›compliance,10 and taking part in other trials3;
23 related to treatment: taking anticoagulants11 or tak›
ing corticosteroids12; and 10 related to drug sensitivi›
ties: granuflex,6 methylxanthines,2 and multiple drugs,2
The duration of treatment was either until all ulcers
on the designated trial leg were healed—that is, fully
epithelialised—or until 24 weeks of treatment had been
completed. The randomised dressings were a knitted
viscose dressing (NA; Johnson and Johnson, Ascot) or a
hydrocolloid dressing (Improved Formulation Granu›
flex; ConvaTec, Uxbridge). The randomised compres›
sion treatments were an elastic single layer method
(Granuflex Adhesive Compression Bandage; Con›
vaTec), or a four layer bandaging regimen (Velband;
Johnson and Johnson), crŒpe (Smith and Nephew,
Hull), elset (Seton, Oldham), and coban (3M,
Loughborough) applied by standardised bandaging
techniques. Patients attended weekly for renewal of
their dressings. Healing was monitored by tracing the
ulcers on entry and at intervals of 4 weeks. The tracings
were subsequently measured by planimetry (not
reported here).
If the treatment was known to be interrupted for
longer than 14 days for whatever reason during the
course of the trial, the patient continued to be followed
up but was withdrawn from the study and analysed as a
failure of treatment. To monitor compliance all used
and unused treatment containers were recovered at
each monthly visit and when each patient completed
the trial, and these were returned to the manufacturer
for checking. Tablet counts were conducted at the end
of the study.
Measurements of outcome
The principal efficacy variable was the complete
healing of all ulcers on the reference leg by 24 weeks of
treatment. A secondary efficacy variable was time to
healing.
Results
Overall, 101 patients were randomised to receive pen›
toxifylline and 99 to receive placebo. The groups were
comparable after randomisation (table). Twenty two
patients were withdrawn from the trial, 11 from each
group, but they were included in the analysis as failure
to heal on treatment. Two patients in each group
developed, or were found to have, exclusion criteria
after randomisation. Three patients in the placebo
group and one in the pentoxifylline group discontin›
ued their drug when they were admitted to hospital
with intercurrent illnesses. Two patients taking
pentoxifylline but none taking placebo withdrew
because of gastrointestinal symptoms (box). No signifi›
cant differences were found between the groups. The
drug seemed to be acceptable to most patients and
safe, as adverse reactions that resulted in discontinua›
tion of the drug were few.
Characteristics of pentoxifylline and placebo groups after randomisation. Values are
numbers (percentages) unless stated otherwise
Patients’ characteristics Pentoxifylline (n=101) Placebo (n=99)
Male 30 38
Female 71 61
Former smoker 43 41
Current smoker 14 18
Mean (SD) age (range) 70.8 (11.3) (35›91) 68.1 (8.9) (34›91)
Ulcer details (median, interquartile range)
Years since first ulcer 3 (1›14) 5 (1›20)
No of episodes of ulceration 2 (1›3) 2 (1›3)
Duration of reference ulcer (months) 6 (3›12) 4 (2›9)
Maximum diameter of reference ulcer (mm) 27 (17›41) 29 (18›40)
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Number of ulcers healed
The ulcers of 65 (64%) patients given pentoxifylline
and 52 (53%) given placebo were completely healed
within 24 weeks. The absolute difference in healing
rates was 11% (95% confidence interval 2% in favour of
placebo to 25% in favour of pentoxifylline).
Time to healing
The figure shows that during the first 6 weeks 14% of
the ulcers had healed and that there was little
difference between the pentoxifylline and placebo
groups. After a further week, a slight improvement in
healing rates with pentoxifylline became apparent.
This continued until the end point at 24 weeks when
64% of ulcers were healed in the pentoxifylline group
compared with 53% in the placebo group.
Discussion
Previous studies have suggested that pentoxifylline
might be a useful adjunct to ambulatory compression
bandaging and dressings in the treatment of leg ulcers.
Pemler et al claimed considerable improvements in a
trial of 513 patients with chronic leg ulcers, which was
uncontrolled, unrandomised, without a clear end
point, and with undefined ulcer aetiology.11 One
hundred and sixty of the patients had diabetes. Ramani
et al have since shown that pentoxifylline was beneficial
to healing and prognosis in a trial of 40 patients with
diabetic ulcers.12
In a randomised, controlled trial of 80 patients with
pure venous ulcers, Colgan et al achieved 64% healing
rates with pentoxifylline and 34% with a placebo after
6 months of treatment.14 These results were significant
at the conventional 5% level. The 64% healing rate for
the pentoxifylline group was similar to ours, whereas
that for the placebo was much lower.
We ensured that the ulcer disease was clearly
defined by recruiting only patients with “pure” venous
ulcers and by rigorously excluding those with serious
diseases, such as diabetes, which might have been
affected by giving pentoxifylline and consequently
might have altered the healing rates. Two hundred
patients, on the basis of 80% power to detect
statistically significant differences if the true healing
rates at a fixed time were 60% and 40%, was a
sufficiently large number to show an effect of pentoxi›
fylline on ulcer healing if such existed.
As there were no differences in healing rates
between the groups during the first 6 weeks of
treatment, a short treatment period would not have
produced a clear result. The trial duration of 24 weeks
allowed sufficient time to show whether there were dif›
ferences in healing rates between the pentoxifylline
and placebo groups. In our trial, slightly more ulcers
were healed with pentoxifylline, and more quickly, than
with the placebo. Within 24 weeks, we achieved 53%
healing in the placebo group and 64% in the pentoxi›
fylline group, but this difference was not significant at
the 0.05 level.
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Reasons for withdrawal from trial
(pentoxifylline group, placebo group)
• Side effects
Gastrointestinal symptoms (2, 0)
Headaches (0, 2)
Sleep disturbance (1, 0)
Hot flushes (1, 0)
Unpleasant feelings (0, 1)
• No reason given (0, 1)
• Trial drug stopped when patient was admitted to
hospital (1, 3)
• Intercurrent illness (1, 0)
• Exclusion criteria discovered or developed after
entry to trial (2, 2)
• Drug omitted (no specific reason given) for more
than 14 days (1, 2)
• Died (2, 0)
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Key messages
x Leg ulcers cost the NHS around £400 million
per annum
x 50%›75% of venous leg ulcers can be succesfully
treated with dressings and compression
bandages but take many months to heal
x A drug that reduced the healing time of venous
ulcers would be useful, although no agent has
been proved to be effective to date
x Trials with pentoxifylline, a vasoactive drug used
in the treatment of peripheral vascular diseases,
as an adjunct to the treatment of venous ulcers
have been inconclusive
x At the 5% level, pentoxifylline had a
non›significant effect on healing rates of pure
venous ulcers
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Nutritional status and mortality of refugee and resident
children in a non›camp setting during conflict:
follow up study in Guinea›Bissau
Peter Aaby, Joaquim Gomes, Manuel Fernandes, Queba Djana, Ida Lisse, Henrik Jensen
Abstract
Objective To study the effects on children of
humanitarian aid agencies restricting help to refugee
families (internally displaced people).
Design Follow up study of 3 months.
Setting Prabis peninsular outside Bissau, the capital of
Guinea›Bissau, which has functioned as a refugee area
for internally displaced people in the ongoing war,
and the study area of the Bandim health project in
Bissau.
Participants 422 children aged 9›23 months in 30
clusters.
Main outcome measures Mid upper arm
circumference and survival in relation to residence
status.
Results During the refugee situation all children
deteriorated nutritionally, and mortality was high
(3.0% in a 6 week period). Rice consumption was
higher in families resident in Prabis than in refugees
from Bissau but there was no difference in food
expenditure. Nutritional status, measured by mid›
upper arm circumference, was not associated with rice
consumption levels in the family, and the decline in
circumference was significantly worse for resident
than for refugee children; the mid›upper arm
circumference of refugee children increased faster
than that of resident children. For resident children,
mortality was 4.5 times higher (95% confidence
interval 1.1 to 30.0) than for refugee children.
Mortality for both resident and refugee children was
7.2 times higher (1.3 to 133.9) during the refugee’s
stay in Prabis compared with the period after the
departure of the refugees.
Conclusion In a non›camp setting, residents may be
more malnourished and have higher mortality than
refugees. Major improvements in nutritional status
and a reduction in mortality occurred in resident and
refugee children as soon as refugees returned home
despite the fact that there was no improvement in
food availability.
Introduction
The health of refugees and displaced people has been
mainly studied in camp settings,1–3 which has strongly
influenced the way such people are treated. During the
current crisis in Guinea›Bissau,4 there have been no
camps1; all refugees have lived with either relatives,
friends, or strangers, and utilised their resources. The
international emergency agencies, the World Food
Programme and the International Committee for the
Red Cross, however, restricted food aid to the
estimated 350 000 refugees (internally displaced
people). This was thought both unjust and unjustified
by Guineans and local expatriates concerned with
humanitarian aid. Since the policies of international
and local organisations represent different under›
standings of the implications of the displacement of
people, and since there has been little research on the
consequences of non›camp settings, we examined
health outcomes for both refugee and resident
children.
Participants and methods
On 7 June 1998, armed conflict started in Guinea›
Bissau between rebel soldiers (military junta) and the
government army, which 3 days later received the sup›
port of troops from neighbouring countries Senegal
and Guinea. The arrival of the foreign troops provoked
a fully fledged war and the capital, Bissau, was shelled
heavily by rebel artillery.
Nearly all 300 000 inhabitants of Bissau had fled
the city by mid›June. Around 50 000 of the fleeing
people took refuge just 5›15 km outside Bissau in the
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